全文获取类型
收费全文 | 985篇 |
免费 | 60篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 35篇 |
妇产科学 | 7篇 |
基础医学 | 84篇 |
口腔科学 | 22篇 |
临床医学 | 92篇 |
内科学 | 229篇 |
皮肤病学 | 17篇 |
神经病学 | 42篇 |
特种医学 | 135篇 |
外科学 | 99篇 |
综合类 | 37篇 |
预防医学 | 68篇 |
眼科学 | 45篇 |
药学 | 55篇 |
中国医学 | 2篇 |
肿瘤学 | 80篇 |
出版年
2024年 | 1篇 |
2023年 | 9篇 |
2022年 | 18篇 |
2021年 | 46篇 |
2020年 | 21篇 |
2019年 | 18篇 |
2018年 | 32篇 |
2017年 | 21篇 |
2016年 | 36篇 |
2015年 | 35篇 |
2014年 | 48篇 |
2013年 | 56篇 |
2012年 | 55篇 |
2011年 | 82篇 |
2010年 | 54篇 |
2009年 | 67篇 |
2008年 | 70篇 |
2007年 | 67篇 |
2006年 | 57篇 |
2005年 | 40篇 |
2004年 | 17篇 |
2003年 | 15篇 |
2002年 | 8篇 |
2001年 | 6篇 |
2000年 | 5篇 |
1999年 | 5篇 |
1998年 | 17篇 |
1997年 | 11篇 |
1996年 | 18篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 18篇 |
1992年 | 6篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 10篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 10篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1975年 | 2篇 |
排序方式: 共有1051条查询结果,搜索用时 187 毫秒
1.
2.
3.
4.
青蒿琥酯皮肤擦剂在小鼠和兔体内的药代动力学研究 总被引:1,自引:0,他引:1
将青蒿琥酯溶于苯二甲酸二甲酯,加适量氨酮制成皮肤擦剂。给兔脱毛后,皮肤涂抹此擦剂25mg/kg后,血药浓度达峰时间平均为2 h,峰浓度平均为1.80μg/ml。药物在兔体内平均驻留时间为3.54 h,清除半衰期约为2.46 h。给小鼠脱毛皮肤涂抹擦剂6.7,31.3和71.4 mg/kg,血药浓度在给药后0.5~4 h达高峰,峰浓度分别为0.82,2.05和7.11μg/ml,体内药物平均驻留时间为3.39,2.79及3.54 h,清除半衰期为2.35,1.93及2.45 h。可见,给兔及小鼠皮肤擦剂后,青蒿琥酯吸收良好,血药浓度维持时间较长。 相似文献
5.
6.
7.
8.
9.
Beomyoung Cho Jana L. Hirschtick Bukola Usidame Rafael Meza Ritesh Mistry Stephanie R. Land David T. Levy Theodore Holford Nancy L. Fleischer 《The Journal of adolescent health》2021,68(4):750-757
PurposeThis study examines sociodemographic patterns of exclusive/dual/polytobacco use among U.S. high school students using multiple national surveys.MethodsUsing three national youth surveys (Population Assessment of Tobacco and Health [PATH] Wave 4 [2016–2017], 2017 Youth Risk Behavior Survey, and 2017 National Youth Tobacco Survey), we classified tobacco products into four groups: (1) electronic nicotine delivery systems (ENDS), (2) conventional cigarettes (CCs), (3) other combustible tobacco products, and (4) smokeless tobacco products. We created 16 categories of non/exclusive/dual/polytobacco use within the past 30 days using the four product groups and calculated weighted population prevalence by sex and race/ethnicity (all surveys) and parental education and income (PATH), based on variable availability.ResultsThe results from 9,331, 12,407, and 9,699 high school students in PATH, Youth Risk Behavior Survey, and National Youth Tobacco Survey, respectively, largely agreed and pointed to similar conclusions. ENDS was the most prevalent exclusive use product (3.8%–5.2% across surveys), with CCs falling to second or third (1.2%–2.0% across surveys). By sex, exclusive, dual, and poly smokeless tobacco product use were more common for males, whereas exclusive CC use was more common for females. By race/ethnicity, non-Hispanic Whites had a higher prevalence of exclusive ENDS use and ENDS/CC dual use than non-Hispanic Blacks. As income and parental education levels increased from low to high, the prevalence of exclusive CC use decreased, whereas the prevalence of exclusive ENDS use increased.ConclusionUnderstanding sociodemographic patterns of tobacco use can help identify groups who may be at greater risk for tobacco-related health outcomes. 相似文献
10.
Grace Montepiedra Ritesh Ramchandani Sachiko Miyahara Soyeon Kim 《Statistics in medicine》2021,40(2):327-348
When a new treatment regimen is expected to have comparable or slightly worse efficacy to that of the control regimen but has benefits in other domains such as safety and tolerability, a noninferiority (NI) trial may be appropriate but is fraught with difficulty in justifying an acceptable NI margin that is based on both clinical and statistical input. To overcome this, we propose to utilize composite risk‐benefit outcomes that combine elements from domains of importance (eg, efficacy, safety, and tolerability). The composite outcome itself may be analyzed using a superiority framework, or it can be used as a tool at the design stage of a NI trial for selecting an NI margin for efficacy that balances changes in risks and benefits. In the latter case, the choice of NI margin may be based on a novel quantity called the maximum allowable decrease in efficacy (MADE), defined as the marginal difference in efficacy between arms that would yield a null treatment effect for the composite outcome given an assumed distribution for the composite outcome. We observe that MADE: (1) is larger when the safety improvement for the experimental arm is larger, (2) depends on the association between the efficacy and safety outcomes, and (3) depends on the control arm efficacy rate. We use a numerical example for power comparisons between a superiority test for the composite outcome vs a noninferiority test for efficacy using the MADE as the NI margin, and apply the methods to a TB treatment trial. 相似文献